Beta
ManageSearchChatDiscover
320871

Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy at Suez Canal University Hospital, Ismailia, Egypt

Article

Last updated: 04 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

Clinical Research (Medical)

Abstract

Background: Limited studies measured the proportion of persistent ovarian escape (OE) in breast cancer patients on ovarian suppression (OS) therapy. Aim: To investigate persistent OE in premenopausal breast cancer patients on OS therapy and its correlation to clinical data and early clinical outcomes. Methods: This was a retrospective study, evaluating the percentage of persistent OE in premenopausal women on OS therapy within 3, 6, 9, 12, and 18 months of goserelin acetate injections. Demographic data, histopathological, hormonal receptor status, stage, and treatment received were retrieved from files of 143 eligible patients attending the Clinical Oncology and Nuclear Medicine department, Suez Canal University, Hospitals, Ismailia, Egypt. Blood Hormonal levels were assessed quarterly for the first year and then after 6 months. Results: 88 (61%) patients showed OE within the first 3 months. The OE group was significantly younger than the OS group (mean age 38.26 and 42.47 years for OE and OS group, respectively) (p value <0.001). The mean BMI was higher in the OE group (32.8 kg/m2) compared to the OS group (31.2 kg/m2) and was statistically significant (p value 0.020). Rates of ovarian escape were significantly higher in women who were receiving aromatase inhibitor versus tamoxifen (94.7% vs. 49.5%) (p value <0.001). Also, OE group has slightly lower disease-free survival compared to OS group. Conclusions: A significant percentage of patients did not achieve OS after 3 months of OS therapy. That was associated with younger age and higher BMI. OS was slightly better regarding disease-free survival than OE group.
 

DOI

10.21608/scumj.2023.320871

Keywords

Ovarian Escape, ovarian suppression, Premenopausal, breast cancer

Authors

First Name

Salma

Last Name

Darwish

MiddleName

-

Affiliation

Department of Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Email

salma.yehia@med.suez.edu.eg

City

-

Orcid

-

First Name

Ahmed M.

Last Name

Elzawawy

MiddleName

-

Affiliation

Department of Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Email

-

City

-

Orcid

-

First Name

Marwa

Last Name

Suliman

MiddleName

-

Affiliation

Department of Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Email

marwa_awad2008@yahoo.com

City

-

Orcid

-

First Name

Fifi E.

Last Name

Mostafa

MiddleName

-

Affiliation

Department of Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Email

-

City

-

Orcid

-

Volume

26

Article Issue

7

Related Issue

42539

Issue Date

2023-07-01

Receive Date

2023-10-10

Publish Date

2023-07-01

Page Start

10

Page End

18

Print ISSN

1110-6999

Online ISSN

2090-2581

Article File

SCUMJ_Volume 26_Issue 7_Pages 10-18.pdf

PDF . 282.6kB

Link

https://scumj.journals.ekb.eg/article_320871.html

Detail API

https://scumj.journals.ekb.eg/service?article_code=320871

Order

2

Type

Original Article

Type Code

938

Publication Type

Journal

Publication Title

Suez Canal University Medical Journal

Publication Link

https://scumj.journals.ekb.eg/

MainTitle

Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy at Suez Canal University Hospital, Ismailia, Egypt

Details

Type

Article

Created At

24 Dec 2024